Literature DB >> 11097088

Expression of the aryl hydrocarbon receptor/transcription factor (AhR) and AhR-regulated CYP1 gene transcripts in a rat model of mammary tumorigenesis.

A F Trombino1, R I Near, R A Matulka, S Yang, L J Hafer, P A Toselli, D W Kim, A E Rogers, G E Sonenshein, D H Sherr.   

Abstract

Exposure to ubiquitous environmental chemicals, such as polycyclic aromatic hydrocarbons (PAH), may contribute to human breast cancer. In animals, PAH induce tumors in part by activating the aryl hydrocarbon receptor (AhR)/transcription factor. Historically, investigations into AhR-regulated carcinogenesis have focused on AhR-dependent transcriptional regulation of cytochrome P450 (CYP) enzymes which oxidize PAH to mutagenic intermediates. However, recent studies suggest that the AhR directly regulates cell growth. Given the postulated role of the AhR in carcinogenesis, we predicted that: (1) tissue predisposed to PAH tumorigenesis would express the AhR and (2) aberrant AhR and/or AhR-regulated gene expression would accompany malignant transformation. To test these hypotheses, AhR and CYP1 protein and/or mRNA levels were evaluated in rat mammary tumors induced with 7, 12-dimethylbenz[a]anthracene (DMBA), a prototypic PAH and AhR ligand. Results indicate modest AhR expression in normal mammary myoepithelial and ductal epithelial cells. In contrast, high AhR levels were detected in DMBA-induced tumors. Nuclear AhR localization in tumors suggested constitutive AhR activation. In situ hybridization and quantitative RT-PCR assays indicated high AhR mRNA levels in neoplastic epithelial cells. While both AhR-regulated CYP1A1 and CYP1B1 mRNAs were induced in breast tissue within 6 h of DMBA gavage, only CYP1B1 mRNA remained elevated in tumors. These results: (1) help explain targeting of breast tissue by carcinogenic PAH, (2) imply that AhR and CYP1B1 hyper-expression represent molecular biomarkers for, at least, PAH-induced mammary cell transformation, and (3) suggest mechanisms through which the AhR may contribute to carcinogenesis well after exogenous AhR ligands have been eliminated.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11097088     DOI: 10.1023/a:1006443104670

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  29 in total

1.  Aryl hydrocarbon receptor activation during pregnancy, and in adult nulliparous mice, delays the subsequent development of DMBA-induced mammary tumors.

Authors:  Tao Wang; Heather M Gavin; Volker M Arlt; B Paige Lawrence; Suzanne E Fenton; Daniel Medina; Beth A Vorderstrasse
Journal:  Int J Cancer       Date:  2010-06-02       Impact factor: 7.396

2.  In silico identification of an aryl hydrocarbon receptor antagonist with biological activity in vitro and in vivo.

Authors:  Ashley J Parks; Michael P Pollastri; Mark E Hahn; Elizabeth A Stanford; Olga Novikov; Diana G Franks; Sarah E Haigh; Supraja Narasimhan; Trent D Ashton; Timothy G Hopper; Dmytro Kozakov; Dimitri Beglov; Sandor Vajda; Jennifer J Schlezinger; David H Sherr
Journal:  Mol Pharmacol       Date:  2014-08-26       Impact factor: 4.436

Review 3.  Regulation of constitutive and inducible AHR signaling: complex interactions involving the AHR repressor.

Authors:  Mark E Hahn; Lenka L Allan; David H Sherr
Journal:  Biochem Pharmacol       Date:  2008-09-20       Impact factor: 5.858

4.  Malignant transformation of mammary epithelial cells by ectopic overexpression of the aryl hydrocarbon receptor.

Authors:  J Brooks; S E Eltom
Journal:  Curr Cancer Drug Targets       Date:  2011-06       Impact factor: 3.428

5.  Interaction of aryl hydrocarbon receptor and NF-κB subunit RelB in breast cancer is associated with interleukin-8 overexpression.

Authors:  Christoph Franz Adam Vogel; Wen Li; Dalei Wu; Jamie K Miller; Colleen Sweeney; Gwendal Lazennec; Yasuko Fujisawa; Fumio Matsumura
Journal:  Arch Biochem Biophys       Date:  2011-05-26       Impact factor: 4.013

6.  Dynamic expression of a LEF-EGFP Wnt reporter in mouse development and cancer.

Authors:  Nicolas Currier; Kathleen Chea; Mirka Hlavacova; Daniel J Sussman; David C Seldin; Isabel Dominguez
Journal:  Genesis       Date:  2010-03       Impact factor: 2.487

7.  Epigenome modulated xenobiotic detoxification pathways control DMBA-induced breast cancer in agouti Avy/a mice.

Authors:  Simbarashe Mazambani; Madeleine Morris; Venugopalan Cheriyath
Journal:  Epigenetics       Date:  2019-05-09       Impact factor: 4.528

8.  A novel role of the aryl hydrocarbon receptor (AhR) in centrosome amplification - implications for chemoprevention.

Authors:  Nina Korzeniewski; Sarah Wheeler; Payel Chatterjee; Anette Duensing; Stefan Duensing
Journal:  Mol Cancer       Date:  2010-06-17       Impact factor: 27.401

9.  Potential therapeutic significance of increased expression of aryl hydrocarbon receptor in human gastric cancer.

Authors:  Tie-Li Peng; Jie Chen; Wei Mao; Xin Liu; Yu Tao; Lian-Zhou Chen; Min-Hu Chen
Journal:  World J Gastroenterol       Date:  2009-04-14       Impact factor: 5.742

10.  Inhibition of constitutive aryl hydrocarbon receptor (AhR) signaling attenuates androgen independent signaling and growth in (C4-2) prostate cancer cells.

Authors:  Cindy Tran; Oliver Richmond; Latayia Aaron; Joann B Powell
Journal:  Biochem Pharmacol       Date:  2012-12-22       Impact factor: 5.858

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.